Clinical trial
Phase 2 Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients: the PONALLO Trial."
NCT03690115 is registered in ClinicalTrials.gov with Versailles Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients: the PONALLO Trial."
- Lead sponsor
- Versailles Hospital
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 2, 2019
- Completion date
- December 31, 2024
- Enrollment
- 23 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.